Xellia is a world-leading trusted developer, manufacturer and supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients and injectable drug products.
With over 100 year history and wholly owned by Novo Holdings A/S, Xellia is developing a pipeline of value-added anti-infective medicines intended to enhancing patient care.